Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.4720 +0.0020 (+0.43%)
Streaming Delayed Price Updated: 8:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
From Lineage Cell Therapeutics
Via Business Wire
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of General Counsel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.